Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2001

View Archived Issues

Baxter acquires epoetin omega for treating anemia

Angiogene secures further R&D funding

OGS achieves solid progress during first half of 2001

Up to 61% genital wart clearance obtained in phase III trial of Polyphenon E

Fujisawa will market Atrisone in North America

FDA advisory committee decision on Diovan for heart failure indication

Data from three pediatric trials demonstrate efficacy and safety of atomoxetine in ADHD

First approval granted for Spiriva in The Netherlands for treatment of COPD

Lundbeck terminates R&D agreement with Neurochem

Once-daily Adderall XR approved by FDA for ADHD; registration trial discussed at CNS meeting

Reduction in recurrent renal flares and high-dose corticosteroids in LJP-394-treated lupus patients

Phase II clinical trials commence with Transgene's immunotherapeutic for cervical cancer

U.S. phase III efficacy and safety data for Foznol discussed at World Congress of Nephrology

Idec and Mitsubishi extend IDEC-114 collaboration

Ergo Science completes restructuring

Inotek NO-releasing compound shows promise in sheep model of acute lung injury

CeNeS reports progress with pain portfolio during first half of 2001

Adenovirus-mediated IL-10 gene therapy may have potential in the treatment of osteolysis

Potent elastase inhibitors with low toxicity reported by Cermol

Roche prepares series of selective 5-HT2B and/or 5-HT2C agonists

New ketolide antibiotics patented by Pfizer

Anti-H. pylori agents identified by Bayer scientists

Indian group designs peptide antagonists of bombesin and related peptides for cancer Rx

Recent patent covers inhibitors of TGF-beta signaling in development at GSK

XTL Biopharmaceuticals and Biostapro commence antiinfective collaboration

Hybrigenics and Institut Pasteur extend scientific alliance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...